Physician confidence suggests durable momentum
The most revealing signal comes from physician enthusiasm for next-generation metabolic agents: roughly 70% of our surveyed physicians report high likelihood to prescribe specific GLP-1s within six months of launch, across both CKD and HF. Recognition of the cross-condition promise of metabolic intervention is further echoed by more than 50% of surveyed physicians who consider both GLP-1/GIP dual agonists and standalone GLP-1s as highly promising mechanisms of action [Fig 2]. Treaters are voting with intent. GLP-1s enter the field with momentum already on their side.
Treaters are voting with intent. GLP-1s enter the field with momentum already on their side.
Fig 2: % physicians considering GLP-1s as promising mechanisms of action
CKD
GLP-1 receptor agonists
GLP-1/ GIP dual agonists
HF
GLP-1 receptor agonists
GLP-1/ GIP dual agonists
Source: Ipsos CKD Therapy Monitor (February – April 2026, 220 physicians across US reporting on CKD patients; participating physicians were primary treaters and saw a minimum number of patients. Data collected online); Ipsos CKD Therapy Monitor (February – March 2026, 211 physicians across US reporting on HF patients; participating physicians were primary treaters and saw a minimum number of patients. Data collected online). ‘Promising’ defined as 6 or 7 on 7-point scale, where 1 = ‘not at all promising’ and 7 = ‘extremely promising’.
